



PRESS RELEASE

Published: 15-09-2022

Inhalation Sciences signs IRS contract worth 1.39 million SEK with new US respiratory pharma client

ISAB's contract research organization Inhalation Research Services (IRS), has signed a new contract worth 1.39 million SEK (130K Euros) with a US respiratory pharmaceutical company. The new client has chosen ISAB's unique *in vitro* lung simulation tool DissolvIt® for its project.

The current client is a developer of new small molecule treatments for a wide range of respiratory diseases including asthma and COPD. The company has chosen to run dissolution tests on a new substance using ISAB's leading *in vitro* lung simulation tool DissolvIt®.

DissolvIt® has been increasingly recognized in the inhalation industry as a leading solution for generating "IVIVC" data – that is *in vitro* dissolution and absorption data early on in the drug development process that closely predicts later-stage *in vivo* data. Such data can significantly reduce risk and costs early on in drug development.

With a growing body of publications like "*In Vitro to ex Vivo/In Vivo Correlation (IVIVC) of dissolution kinetics from inhaled particulate solutes using air/blood barrier models*" (Journal of Aerosol Science 2021) there is increasing interest in DissolvIt's advanced capabilities.

ISAB CEO Manoush Masarrat: "We are very pleased to be working with this new US client. This clearly demonstrates the client's confidence in our world-class expertise, and the leading *in vitro* capabilities of DissolvIt®. We are delighted to carry out this research and look forward to this exciting collaboration."

Explore DissolvIt's extensive *in vitro* capabilities [here](#).

Read ISAB's publications on DissolvIt® [here](#).

For more information about Inhalation Sciences, please contact:

Manoush Masarrat, CEO

E-mail: Manoush.masarrat@inhalation.se

Mobile: +46 (0)73 628 9153

About Inhalations Sciences Sweden AB (publ)

Inhalation Sciences Sweden AB (publ) develops and commercializes world-leading instruments and services for research into inhalation. The company's patented lab instruments PreciseInhale® and Dissolv *It*® enable researchers in the pharma industry to make drug pipeline decisions at an early stage, saving time and resources for R&D departments, and enables researchers in academic institutions to define how aerosols and small particles impact our lungs, and so our health, when being inhaled.

The information above was provided by Inhalation Sciences Sweden AB according to EU Market Abuse Regulations. The information was provided, through the above contact person, for publication on 15 September, 2022.